ORGANIZING FOR KNOWLEDGE GENERATION: INTERNAL KNOWLEDGE NETWORKS AND THE CONTINGENT EFFECT OF EXTERNAL KNOWLEDGE SOURCING

KONSTANTINOS GRIGORIOU •* and FRANK T. ROthaERmEL

1 College of Business, Florida International University, Miami, Florida, U.S.A.
2 Scheller College of Business, Georgia Institute of Technology, Atlanta, Georgia, U.S.A.

Research summary: When faced with a new technological paradigm, incumbent firms can opt for internal development and/or external sourcing to obtain the necessary new knowledge. We explain how the effectiveness of external knowledge sourcing depends on the properties of internal knowledge production. We apply a social network lens to delineate interpersonal, intra-firm knowledge networks and capture the emergence of two important firm-level properties: the incumbent’s internal potential for knowledge recombination and the level of knowledge coordination costs. We rely on firm-level internal knowledge networks to dynamically track the emergence of these properties across 106 global pharmaceutical companies over a 25-year time period. We find that a firm’s success in developing knowledge in a new technological paradigm using external knowledge sourcing is contingent on these internal knowledge properties.

Managerial summary: Incumbent firms in high-tech industries often face competence-destroying technological change. In their effort to adapt and develop new knowledge in a novel paradigm, incumbent firms have several corporate strategy options available to them: internal knowledge development and a wide array of external knowledge sourcing strategies, including alliances and acquisitions. In this study, we make an effort to address a critical question: How effective is external knowledge sourcing under different internal knowledge generation regimes? We find that external sourcing strategies are less effective when firms can already internally generate new knowledge or if they have high internal coordination costs. Therefore, when considering external sourcing, managers must carefully weigh the benefits of it vis-à-vis its commensurate costs as the benefits of external sourcing may be overstated. Copyright © 2016 John Wiley & Sons, Ltd.

INTRODUCTION

Competence-destroying technological change poses significant challenges for an industry’s incumbent firms (Tushman and Anderson, 1986).

Keywords: organizing • for adaptation; internal knowledge networks; innovation strategies; complementarities; external knowledge sourcing

*Correspondence • to: Konstantinos Grigoriou.
E-mail: kgrigori@fiu.edu

To build knowledge within a new technological paradigm, incumbents invest in internal knowledge development (Tripsas, 1997), human capital (Zucker and Darby, 1997), strategic alliances (Rothaermel, 2001), acquisitions of new entrants (Higgins and Rodriguez, 2006), or in combinations of those strategies (Rothaermel and Hess, 2007). There is a significant degree of consensus in the strategy literature that successful renewal depends on incumbents developing skills in both internal
knowledge development and external knowledge sourcing (Helfat et al., 2007).

Clearly, both internal development and external sourcing have received considerable attention in the literature as more or less isolated strategic choices. We have a somewhat limited understanding, however, about the conditions that favor one sourcing mode over the other. Capron and Mitchell (2009) echo this statement when arguing that a firm’s selection capability, defined as the ability to choose among modes of knowledge sourcing, is an underemphasized form of capability. Further, Nickerson and Zenger (2004: 1) suggest that the key question is not “how to organize to exploit already developed knowledge or capability, but rather how to organize to efficiently generate knowledge and capability.”

We contribute to this line of burgeoning research by applying social network concepts to address the question of how to organize and choose among knowledge sourcing efforts to efficiently generate new knowledge. We predict the effectiveness of knowledge sourcing strategies for incumbent firms trying to develop new knowledge within an emerging technological paradigm. We track their internal and external sourcing activities in a fine-grained manner as they co-evolve over time. As the incumbent firms generate new knowledge, we use collaborative network analysis to capture important properties of their internal knowledge production process. In particular, we look deep inside the firm to track the interpersonal networks of knowledge workers to assess not only the value created by knowledge generation, but also its production costs. To track external sourcing, we examine the incumbents’ activity with knowledge-related alliances and acquisitions.

Our core argument is that the effectiveness of a firm’s external knowledge sourcing strategies to build new knowledge is contingent on the properties of that firm’s internal knowledge production. We focus on two such properties: the firm’s potential for subsequent internal knowledge recombination and the knowledge coordination costs associated with its existing knowledge production system. We explain why external sourcing is bound to be less effective for new knowledge generation for firms that either already possess strong potential for further knowledge recombination internally or already incur high coordination costs in their existing knowledge production process.

To proxy for these firm-level properties, we look at fine-grained internal knowledge networks and we rely on the concept of emergence (Kozlowski et al., 2013). We explain how the structure and evolution of interpersonal knowledge networks inside incumbent firms result in the emergence of firm-level knowledge properties such as recombinative potential and coordination costs. In essence, we describe how firm-level network properties emerge from internal individual-level network structures and interactions (Moliterno and Mahony, 2011). In short, we argue that differences across firms in these knowledge network properties drive the contingent effect of their external knowledge sourcing choices on their knowledge generation within a new technological paradigm.

The novel contribution in our study results from the application of social network concepts to develop a fine-grained picture of the state of a firm’s internal knowledge production process, and to capture the potential for knowledge recombinative and accompanying coordination costs. Moreover, this fresh approach enables us to document the role of the firm’s internal knowledge network as an important but overlooked contingency factor when evaluating the effectiveness of external knowledge sourcing choices. As a result, we also offer a significant contribution to the growing literature on knowledge networks and their importance for firm performance (Phelps, Heidl, and Wadhwa, 2012).

Empirically, we examine the phenomenon using large but detailed longitudinal panel datasets of both firms and individual inventors within these firms. When estimating the contingent effects of external knowledge sourcing choices, we dynamically update the firms’ internal knowledge networks to address the co-evolution of internal knowledge and knowledge sourcing choices. We test the theoretical framework in the global pharmaceutical industry, where we track the innovative activities of 106 incumbent firms in their effort to adapt to the new biotechnology paradigm over a 25-year period (1974–1998). We rely on the firms’ patenting portfolios of more than 267,000 individual inventors to build internal networks for biotech knowledge generation. We apply network theory to extract information from intra-firm networks about the individual inventors’ network positions, the overall network structure, and subsequently, the firms’ knowledge properties of knowledge recombinative potential and coordination costs in its knowledge production process.

To foreshadow our conclusions, we submit that selecting a specific path to develop new
knowledge is a highly consequential strategic choice driving firm-level heterogeneity. Although external sourcing using alliances and acquisitions has well-documented independent benefits for new knowledge generation, we argue herein that external sourcing is not as effective, in some cases even harmful, when combined with a certain state of internal knowledge production. We conclude by discussing theoretical implications of this work on boundary choices, knowledge generation, and knowledge networks. We also highlight managerial implications concerning the contingent effects of external knowledge sourcing on new knowledge development.

THEORY

One of the most enduring themes in strategy research is the mandate for incumbent firms to undertake knowledge sourcing strategies in the face of environmental changes (Agarwal and Helfat, 2009). One question that has received significant attention is how firms choose their boundaries for new knowledge generation. We know that firms may favor external sourcing because of a preference for outsiders’ knowledge (Menon and Pfeffer, 2003), internal social comparison costs (Nickerson and Zenger, 2004), or availability of knowledge suppliers and an intense competitive environment (White, 2000). Firms may also choose external sourcing because of dyadic considerations such as knowledge fit (Baum, Cowan, and Jonard, 2010), status similarity (Chung, Singh, and Lee, 2010), or mutual trust through fairness with potential partners (Ariño and Ring, 2010). Firm-specific explanations such as the depth of the firm’s internal knowledge base have also been documented as drivers of the internal versus external sourcing choice (Zhang and Baden-Fuller, 2010).

In parallel, several insightful studies have addressed the question of implementation, that is: How can firms effectively use different external sourcing modes to build new knowledge? For example, prior work has shown how firms can maximize the effectiveness of alliances by altering intra-alliance value appropriation regimes (Adebesan and Higgins, 2011), alliance scope (Oxley and Sampson, 2004), or alliance learning objectives (Kale, Dyer, and Singh, 2002; Rothaermel and Deeds, 2004). In addition, others have documented how firms can increase the benefits of acquisitions by increasing the size of the acquired knowledge base (Ahuja and Katila, 2001) by acquiring information about the targets’ R&D activities prior to the acquisition (Higgins and Rodriguez, 2006), by relying on complementary knowledge (Makri, Hitt, and Lane, 2010), and by altering the level of post-acquisition integration (Puranam, Singh, and Chaudhuri, 2009). Taken together, novel theoretical work combined with careful empirical analysis has provided an understanding of the factors that drive knowledge boundary choices and of the levers that can increase the effectiveness of various knowledge sourcing initiatives.

There is, however, mounting evidence that firms increasingly rely on a combination of internal and external sourcing (Capron and Mitchell, 2009; Chesbrough, 2003; Parnigiani, 2007; Parnigiani and Mitchell, 2009). We have some evidence about factors affecting the degree of complementarity between external and internal sources of knowledge: the firms’ absorptive capacity (Cohen and Levinthal, 1990), intellectual property considerations and the type of research and development conducted (Cassiman and Vugelers, 2006), interactions across levels of analysis (Rothaermel and Hess, 2007), capability differences across vertical value chain segments (Jacobides, 2008), and the type of experience in different learning stages (Hoang and Rothaermel, 2010). The idea that it is differences in internal knowledge bases that essentially drive boundary choices has also been highlighted before (Jacobides and Hitt, 2005; Jacobides and Winter, 2005; Kogut and Zander, 1992). Therefore, beyond understanding how firms choose their knowledge boundaries and examining ways to increase the effectiveness of independent sourcing strategies, we need to better understand the conditions that make external sourcing effective when combined with the firm’s existing stock of internal knowledge. This is where we aim to provide a theoretical and empirical contribution.

In particular, we observe that firms are endowed with an internal capability for knowledge generation as a consequence of past internal knowledge development and external knowledge sourcing choices. We argue herein that the state of a firm’s internal knowledge production process determines the effectiveness of external knowledge sourcing. Importantly, by choosing this atomistic perspective, we do not reject the importance of dyadic or network views. Instead, we believe that the atomistic
view, which is the traditional lens in strategic management and focuses on the firm itself rather than its position in a larger network or its dyadic relationships, is in line with our emphasis on the selection question between external and internal knowledge sourcing strategies. We argue that when a firm’s knowledge production process is characterized by certain knowledge network properties, then external knowledge sourcing may be more or less appropriate for new knowledge generation.

Essentially, we address the question of organizational design for knowledge building (Madhok, 2002). In this line of thought, differences in knowledge bases determine firm boundaries (Kogut and Zander, 1992). Here, we focus on a similar interaction between internal knowledge and knowledge sourcing choices when firms determine their knowledge scope. We dynamically track a firm’s internal knowledge base as it evolves over time, and argue that the effectiveness of external knowledge sourcing is contingent on properties of a firm’s knowledge base; more specifically, the firm’s potential for subsequent internal knowledge recombination and the associated coordination costs. We suggest that when a firm’s internal knowledge network exhibits properties of either high potential for knowledge recombination or high knowledge coordination costs, then external knowledge sourcing is less effective.

Two insightful studies are closely related to our work in that the authors explicitly examine the effectiveness of external knowledge sourcing under various organizational conditions. Nickerson and Zenger (2004) argue that it is the problem type (e.g., its level of decomposability) that dictates the efficiency of alternative knowledge sourcing strategies. Capron and Mitchell (2009) show that the effectiveness of external renewal modes in building new resources depends on the size of the capability gap between current and needed resources, and on the level of internal constraints that arise for the internal social context.

Building on this prior work, we highlight the importance of two additional internal firm-level properties: the firm’s potential for future knowledge recombination in the new knowledge area and the coordination costs associated with its internal knowledge generation process. Importantly, our specific theoretical contribution is the application of social network thinking to a firm’s internal knowledge network in order to capture recombinative potential and coordination costs, and in turn, show how these two properties drive the effectiveness of external knowledge sourcing.

Central to our argument is a move from examining a firm’s internal interpersonal knowledge networks, which emerge as the firm builds knowledge in the new paradigm, to inferring the state of the firm’s internal knowledge properties. In what follows, we detail our logic to justify this link. As incumbents make an effort to adapt to new technology using internal and external sourcing investments, individuals deep within firms collaborate to develop new knowledge. At the firm level, this activity of interpersonal collaboration results in extensive knowledge networks with the objective of new knowledge generation. The nodes of these networks are individuals participating in knowledge production. Ties between individuals reflect direct collaboration with the objective of knowledge co-creation.

HYPOTHESES DEVELOPMENT

Our baseline argument concerning Hypothesis 1 is the following: One of the main benefits of external knowledge sourcing is the fact that it provides a firm with access to new knowledge. If the firm already has the capability to internally recombine existing knowledge to create novel insights, then the positive knowledge effect of external sourcing is likely to be diminished to some extent. In other words, under these conditions, external sourcing becomes a substitute for internal knowledge sourcing.

It is important to note that we hypothesize these effects to be at the margin, and not complete substitution. In particular, two activities interact as substitutes if the marginal benefit of each activity decreases in the presence of the other activity. A simple example illustrates this point: Let’s assume that cardiovascular exercise and a low-cholesterol diet are substitutes in achieving a lower risk of heart disease. The important point here is that although cardiovascular exercise can still have an absolute positive effect on lowering the risk of heart disease, over and above a low-cholesterol diet, the marginal effect of cardiovascular exercise is diminished in the substitution scenario, and vice versa. Applying this reasoning to our hypothesis, we propose that although external knowledge sourcing might still have an absolute positive effect on the firm’s new knowledge generation capability, over and above its internal knowledge development, the...
marginal effect of any external technology sourcing is diminished when a firm with strong internal development capabilities combines it with external knowledge sourcing.

This substitution effect at the margin can be explained by Ocasio’s (1997) attention-based view of the firm and the not-invented-here (NIH) syndrome (Katz and Allen, 1982). In particular, Ocasio’s (1997) attention-based view of the firm offers a cognitive mechanism explaining this substitution effect: Combining internal and external sourcing places significant pressure on the decision makers’ limited attentional capability. The effect is particularly pronounced in the case of firms trying to respond or adapt to a changing environment as is the case here.

Second, from a behavioral point of view, this substitution of external and internal knowledge can also be explained by the presence of not-invented-here (NIH) syndrome (Katz and Allen, 1982), where internal knowledge producers are biased against external sources of knowledge. The NIH syndrome is also particularly pronounced in the case of firms that have a strong capability in internal knowledge generation. As an illustrative example (drawn from Chesbrough, 2003), Merck’s culture and organizational systems perpetuate the NIH syndrome, which assumes that since they hired the best people, the smartest people in the industry must work for Merck, and so the most promising discoveries must be invented at Merck (included in this study). The pharma company leads the industry in terms of R&D spending because Merck believes that if it is the first to discover and develop a new drug, it would be the first to market. Merck is one of the most successful companies by total number of active R&D projects. Perhaps even more important, Merck’s researchers had been awarded several Nobel Prizes for their breakthrough research, a considerable point of pride for Merck’s personnel. In line with our argument, Merck has the lowest number of new drugs with any external collaborators in the industry.

To capture the knowledge base properties of interest, we examine the structure of these knowledge networks. We conceptualize the process of new knowledge production as a structural knowledge-based process of recombination of existing knowledge stocks (Fleming, 2001). We focus on attributes that can be linked with the firm’s potential for future knowledge recombination. In particular, we focus on two dimensions: the degree of the network’s clustering and its average path length. A highly clustered network indicates a structure that is abundant with cohesive clusters of knowledge production that have been shown to facilitate future knowledge recombination. In other words, if an incumbent firm has internally a knowledge network that exhibits high clustering, it means that the firm has relatively large groups of individuals working together in tight-knit clusters to generate relevant new knowledge. When that happens, we know from prior work that the likelihood of further knowledge recombination increases (Reagans, Zuckerman, and McEvily, 2004). In addition, average path length captures the average distance between any two actors in the network. Longer paths indicate a network that is largely heterogeneous, has extensive range, and relies on significant breadth of knowledge stocks. In other words, if an incumbent firm has an internal knowledge network with high average path length, it means that the firm’s individuals are working in many, diverse, and relatively unrelated knowledge areas. Again, we know from prior work (Reagans and Zuckerman, 2001) that when this happens, the likelihood for promising further knowledge recombination increases.

From these knowledge network attributes, we infer the firm-level property of potential for future knowledge recombination. To accomplish this, we rely on the theoretical concept of multilevel emergence. Kozlowski and Klein (2000) define multilevel emergence as a bottom-up process whereby individual behavior and dynamic interactions result in a higher-level property for the group. In our case, the firm level property of knowledge recombinative potential emerges bottom-up from the structure of individual-level knowledge behavior and interactions. We examine an incumbent firm’s internal knowledge network as it evolves, changes, and dynamically reconfigures itself following new knowledge production. These attributes make it a fertile ground for the emergence of a higher-level property (Kozlowski et al., 2013). Similarly, the emergence of the firm-level property of potential for future knowledge recombination from the individual-level interactions can be seen as emergence from lower-level network interactions (Moliterno and Mahony, 2011; Ployhart and Moliterno, 2011). The firm-level property emerges from the clustering or path length structure of the firm’s knowledge network. Taken together, we argue that if a firm has an internal knowledge
network with high clustering and average path length, then that firm has significant potential for internal future knowledge recombination. This, in turn, should make external sourcing strategies less effective for new knowledge at the margin because the firm is able to effectively generate new knowledge internally.

**Hypothesis 1:** The interaction between external knowledge sourcing and internal knowledge networks characterized by high recombinative potential is negative.

Although the structure of a knowledge network has been used to predict its knowledge generation performance (Brown and Eisenhardt, 1997; Reagans and Zuckerman, 2001), it has not been relied on to capture the level of internal coordination costs. In fact, scholars argue that the importance of coordination costs associated with internal knowledge production has generally been neglected by the theories of boundary choice (Langlois and Foss, 1999).

Yet, Argyres and Silverman (2004) find that a firm with a centralized R&D structure generates more impactful innovations through a reduction in internal coordination costs. In addition, Rawley (2010) documents how increases in internal coordination costs constrain economies of scope.

We build on these insights and argue that if an incumbent firm generates knowledge in a new area and the firm already faces high internal knowledge production and coordination costs, then external knowledge sourcing strategies are less effective for new knowledge generation because they would simply add to the existing coordination burden. It is costly to recognize, evaluate, and appraise external knowledge (Levinthal and March, 1993).

One of the main costs of external sourcing, in particular, is the cost of coordination—firms have to identify partners, work with them, commit resources, actively try to transfer knowledge, monitor progress, make adjustments, and so on. If firms already face high coordination costs internally in their internal knowledge production process, then the coordination burden of external sourcing will be amplified. Any positive knowledge effect of external sourcing should be diminished at the margin. In other words, external sourcing becomes a substitute of an internal knowledge production that exhibits high existing coordination costs.

To capture coordination costs of a firm’s internal knowledge network, we rely on two structural attributes of the network: the average number of collaborative ties that knowledge producers have and the average number of collaborative ties required for a new knowledge stock. More ties on average for every knowledge-generating individual suggest a significant coordination burden for the organization. Developing and maintaining collaborative ties requires time and attention at the individual level, resources that are removed from the individual’s pursuit of knowledge development per se. The average number of ties per new knowledge stock, similarly, suggests elevated coordination costs as every new knowledge stock requires a higher, on average, level of interpersonal collaboration. As a result, these structural network attributes suggest an internal knowledge network with significant coordination costs arising from the knowledge production process.

Following a similar multilevel emergence logic (Kozlowski et al., 2013), the firm-level property of a high coordination burden in the firm’s knowledge production system emerges directly from the individual-level interactions that suggest elevated coordination costs per individual and per new knowledge stock. At the same time, one of the main costs of external knowledge sourcing is the cost of coordination—firms have to identify partners, work with them, commit resources, monitor collaboration, transfer knowledge, make adjustments, and so on. Merely evaluating external knowledge is costly because it requires a commensurate level of absorptive capacity (Lane and Lubatkin, 1998; Levinthal and March, 1993). Taken together, we argue that if a firm has an internal knowledge network characterized by high coordination costs, then external sourcing becomes less effective for new knowledge at the margin because external sourcing adds significantly to the coordination burden, potentially negating any benefit to external sourcing.

**Hypothesis 2:** The interaction between external knowledge sourcing and internal knowledge networks characterized by high coordination costs is negative.

In summary, we highlight both the value creation potential of internal knowledge networks in the form of recombination potential and the associated coordination costs. How many benefits a firm captures from external knowledge sourcing partly depends on its internal knowledge network...
attributes. We therefore explicitly examine the influence of a firm’s network structure on knowledge creation, an unexplored topic in prior research (Phelps et al., 2012). We summarize our conceptual model in Figure 1.

**METHODS**

We test the contingency model developed in the global pharmaceutical industry. The industry experienced a competence-destroying technological discontinuity with the emergence of biotechnology (Pisano, 1996; Tushman and Anderson, 1986). Large incumbent pharmaceutical firms faced tremendous pressures to adapt to the new technological paradigm because their upstream research knowledge was inconsistent with the new technology. The need for large pharma companies to build a new knowledge base was exacerbated by the fact that they failed to innovate through developing new blockbuster drugs, while the R&D expenditures were rising and average sales per drug were falling at the same time (Higgins and Rodriguez, 2006). The pressures to build new knowledge in biotech are illustrated by the following trends: between 1990 and 2000, R&D expenditures grew from $6.8 billion in 1990 to $21.3 billion (17% of revenues); new drug development costs increased from $231 to $802 million; and average sales per patented drug fell from $457 to $337 million.  

To develop new knowledge within the new biotechnology paradigm, incumbent pharma companies invested in internal and external technology sourcing (Pisano, 1996). Internally, pharmaceutical companies invested in building up their research capability and human capital. Externally, the incumbent firms invested in exploration alliances to build new knowledge bases, in exploitation alliances to leverage their existing complementary assets, and in acquisitions of smaller biotechnology firms to capture both tacit and explicit knowledge (Pisano, 2006; Rothaermel and Deeds, 2004). This industry is a viable setting to test our contingency hypotheses about the interactions between external and internal knowledge sourcing. Following investment in internal development and external knowledge sourcing, pharmaceutical incumbents firms were able to slowly build new biotech-related knowledge internally, and thus, adapt to the technological discontinuity. We track this process to capture the development of internal new knowledge in the emerging paradigm from the beginning of the

---

1 All in constant, inflation-adjusted 1999 U.S. dollars.
biotech revolution, and examine the effectiveness of various external knowledge sourcing strategies.

Our sample consists of 106 incumbent pharmaceutical firms worldwide, representing more than 80 percent of global sales in this industry. The year 1974 approximates the beginning of industry research in biotechnology, one year after the invention of a technique to recombine DNA developed by Cohen and Boyer in 1973. To assess how successful incumbent pharmaceutical firms have been in adapting to biotechnology and to avoid a sample selection bias, we tracked all firms in existence in 1974 forward in time. We collected annual data for the knowledge sourcing strategies of those firms over a 25-year period, beginning in 1974 until the end of 1998.

We chose to end our data collection in 1998 to explicitly remain focused on the knowledge adaptation process and also avoid the influence of other major external shocks (such as the Internet or the subsequent wave of horizontal mergers and acquisitions). The biotech revolution was certainly not over in 1998, and of course, neither was the process of adaptation. However, we submit that the lion’s share of knowledge adaptation must have taken place in surviving pharmaceutical incumbents 25 years after the first technological breakthrough leading to the biotech revolution. We believe that tracking 25 years of adaptation in a fine-grained manner, through a panel data setup, is a sufficient length of a time period to uncover insights about knowledge sourcing that may inform incumbent firms trying to adapt to similar shifts in knowledge paradigms today.

We characterize firms in the sample as incumbents because they were active in the pharmaceutical industry focusing on human therapeutics prior to the emergence of biotechnology. Horizontal mergers are fairly common in this industry; when a merger occurred, we combined the data of the merging firms into one entity and continued tracking it forward. Not only did we track the sample forward in time, but we also constructed a detailed “family tree” to trace all firms in existence at the end of the study period back in time to their “ancestors,” all the way back to the beginning of the study. This “family tree” allowed us to identify horizontal mergers with great accuracy. To explicitly control for a horizontal merger event, we created an indicator variable to capture this event.

Taken together, the pharmaceutical industry provides an almost ideal setting for our study because it is as close as strategy researchers can recreate a laboratory experiment. Because the dating of the biotech revolution (post-1973) for the pharma companies is well established, we are able track a sample of firms forward that were all founded prior to the new technology paradigm. In particular, traditional pharma firms were created during a time when chemistry was the foundational science (Galambos and Sturchio, 1998). All pharma firms born within the “old” chemical-based screening paradigm in the sample experienced the same exogenous treatment effect (“emergence of biotech”). This type of “natural experiment” allows us to assess how effective incumbent pharma firms were in adapting to the new knowledge paradigm. We explain the observed heterogeneity by differences in a firm’s internal knowledge network structures combined with its external knowledge sourcing strategies.

We constructed the key dependent and independent variables using patents granted to the firms by the USPTO. Albeit not without problems, patent counts have been used extensively to measure a firm’s new knowledge creation activities and innovative performance (e.g., Ahuja, 2000; Henderson and Cockburn, 1994; Rothaermel and Hess, 2007; Stuart, 2000). Moreover, as demonstrated in the Cohen, Nelson, and Walsh (2000) survey of close to 1,500 manufacturing firms in the United States with in-house R&D activity, patenting in the pharma industry is one of the most important strategic activities, and is mainly done to protect intellectual property. Across 34 different industries surveyed, Cohen et al. (2000) found that patenting in the pharma industry ranks second only to the medical device industry in assessing patents as an effective mechanism to protect intellectual property. This implies that patents are used to protect new knowledge generation, the dependent variable of this study. In addition, Hagedoorn and Cloodt (2003) studied different measures of performance of 1,200 large firms in high-tech industries (aerospace and defense, computers and office machinery, electronics and communications, and pharmaceuticals) and found that in the pharma industry the bivariate correlation between patents and patent citations = 0.78; patents and R&D expenditures = 0.70; and patents and new products = 0.59. This indicates that the overlap in explaining variance across different knowledge-related measures is quite high. Hagedoorn and Cloodt (2003: 1,375) concluded:
“the results of the analysis … indicate that the overlap between each of these four indicators is that great … that in high-tech sectors any of these four indicators [patents, patent citations, R&D expenditures, and new products] could be taken as a measure of innovative performance in the broad sense.”

Although there are some alternatives such as projects in pipeline, new products, or even publications by scientists, we submit that tracking individual-level patenting activity is the most appropriate available source of information for our purpose. Projects or products are much removed in time from the date of actual knowledge production, and publications may be more or less unrelated to applicable product-related firm-level knowledge efforts. Although many of these measures are highly correlated as shown by Hagedoorn and Cloodt (2003), patent counts provide the most appropriate theoretical and empirical fit with our study. The date of patent applications is close in time to the date of knowledge production, and publications may be more or less unrelated to applicable product-related firm-level knowledge efforts. Although many of these measures are highly correlated as shown by Hagedoorn and Cloodt (2003), patent counts provide the most appropriate theoretical and empirical fit with our study. The date of patent applications is close in time to the date of knowledge production. Moreover, patents are strategically important in the pharma industry, providing a strong incentive for companies to patent knowledge that is novel, useful, and non-obvious.2

Taken together, patents by incumbent pharma firms in the new field of biotechnology, therefore, seem to be an appropriate measure to capture new knowledge generation. We used the NBER patent database file (Hall, Jaffe, and Trajtenberg, 2001) to create a patent portfolio for each one of our firms from 1974 to 1998. We tracked all names under which firms patent and collected data for their subsidiaries to capture each firm’s full patenting activity.

**Dependent variable**

To proxy the successful development of knowledge in the emerging biotech paradigm by pharmaceutical incumbents, we relied on the annual count of biotech patents assigned to the firms in our sample. We enhanced the accuracy of the patent count metric by focusing only on biotech patents as dependent variable. This enabled us to obtain a more proximate metric of a firm’s knowledge development in the new paradigm because incumbent pharmaceutical firms did not possess any knowledge base in biotech prior to its emergence. This makes the research design akin to a natural laboratory because all incumbent firms were exposed to the same treatment effect (emergence of biotech), but significant heterogeneity emerged in firms’ capability to develop knowledge and adapt.

To define biotech patents, we relied on the definition of a biotech patent provided by the Patent Technology Monitoring Division (PTMD) of the USPTO. The PTMD provides a list of technology classes and subclasses that capture new knowledge stocks with a strong biotech component. To confirm the validity of this approach, we examined the technology classes in patent portfolios of dedicated biotechnology firms, and we found that our approach of categorizing biotech patents was robust. Finally, to ensure that our measure is as close as possible to the actual date of knowledge generation, we constructed our measure of annual biotech patent counts based on the application date of the patent instead of the grant date.

**Intrafirm knowledge networks**

To capture the state of internal knowledge of incumbent firms in the new biotechnology paradigm over time, we developed intrafirm co-inventing networks for each incumbent firm from 1974 to 1998 based on their biotech patents. Hence, we were able to proxy the level of internal collaboration and knowledge development in biotechnology by looking at the emerging intrafirm co-inventing networks developing in the context of a new technological paradigm. We identified unique individual inventors on these biotechnology patents using the NBER database inventor file based on a combination of last name, first name, and middle name (Hall et al., 2001). When there was still a conflict even after using all three names and correcting misspelled last names, we expanded our matching criteria to include city and state of residence for each inventor. The resulting dataset captures every inventor with unique inventor IDs associated with patents from 1974 to 1998, resulting in more than 267,000 inventors in our sample. This allowed us to develop fine-grained co-inventing networks over time (using UCINET 6). The nodes of the network are individual inventors, and a tie between inventors represents a co-patenting event.

Park, Shin, and Park (2006) demonstrated that patented knowledge depreciates fairly quickly over time. Following their empirical estimates, we considered knowledge through a tie that is older than five years as somewhat out-of-date. We therefore developed networks for every firm using a five-year

---

2 Statutory definition of a patentable invention by USPTO.
rolling window and assigned the resulting values to
the last year of every time window (1982–1986 val-
ues to 1986, 1983–1987 values to 1987, etc.). We
analyzed the networks and tracked several network
metrics at the firm-network level (density, total col-
laborative ties, clustering, average path length, etc.).

Independent variables
To develop our key independent variables, we used
the results of the network analysis to capture the
two main properties of an incumbent firm’s state of
internal knowledge sourcing: recombinatory poten-
tial and coordination costs. First, we measured each
firm’s recombinatory potential using two network
metrics: average path length and degree of clus-
tering. Average path length is the average distance
(steps through ties) between any two inventors in the
firm’s knowledge network. The higher the average
length, the broader is the firm’s knowledge network
base, and therefore, the higher is the potential for
further knowledge recombination. Clustering is the
degree to which the firm’s network is organized
around multiple local neighborhoods of dense
interpersonal collaboration, where arguably knowl-
edge recombination is more likely to occur because
those clusters are more likely to be characterized
by increased motivation to share knowledge,
transfer knowledge, and knowledge of who
knows what.

Second, we measured coordination costs using
two different metrics: average ties per biotech
patent and average ties per inventor. Our objective
was to capture the coordination burden of the firm as
it develops new biotech knowledge internally. Average
ties per biotech patent is one aspect of the coordi-
nation burden as it reflects the average intensity
of collaboration used to generate a biotech patent.

Using the five-year rolling window procedure, in
order to derive a variable for year \( t \), we divided the
total number of collaborative ties used to develop
biotech patents from year \( t-4 \) to year \( t \) by the number
of biotech patents produced in year \( t \). Average ties
per inventor is a second aspect of the coordination
burden as it reflects the average intensity of collabor-
oration per inventor. To construct this variable, we
divided the same total number of collaborative ties
by the total number of inventors participating in
the knowledge production process during the same
five-year window (i.e., the size of the network).

Next, we collected detailed information about
the external knowledge sourcing strategies that
were undertaken by the pharmaceutical incumbents
in our sample. We focused on two such external
capability sourcing modes: knowledge-oriented
alliances with sources of biotech knowledge
(i.e., exploration alliances) and biotech-related
acquisitions (Hayward, 2002; Rothaermel, 2001).
First, we collected data on the alliance history
for every firm in our sample from BioScan and
ReCap, databases that have been successfully used
in prior research on alliances and are considered the
most comprehensive sources for alliance activities
(Schilling, 2008). We tracked the alliances that
incumbent firms in our sample entered with various
sources of biotechnology knowledge (universities
and other research institutions as well as biotech
firms). Following a common procedure in prior
research (Koza and Lewin, 1998; Lavie and
Rosenkopf, 2006; Rothaermel and Deeds, 2004),
we coded grant, research, and R&D alliances as
exploration alliances because these alliances focus
on the enhancement of upstream research and
basic science knowledge. To ensure correct coding,
we used multiple research assistants who coded
independently the alliances in our sample. The
inter-rater reliability was 98 percent, well above the
recommended 70 percent (Cohen et al., 2003). The
resulting variable is an annual count of the total
number of such exploration alliances entered by an
incumbent firm in our sample. Further, we collected
the annual number of biotech-related acquisitions
made by incumbent firms from the SDC Platinum
database (Laamanen and Keil, 2008; Puranam and
Srikanth, 2007). Finally, we calculated interactions
between the two types of external knowledge sourc-
ing and the two sets of internal knowledge sourcing
properties discussed above. Before entering them
into interactions, we standardized all variables,
and also controlled for the direct effects of the
independent variables that make up the interaction
effects.

Control variables
We include a rich and fine-grained set of controls
to limit the threat of endogeneity (Hamilton and
Nickerson, 2003). We control for the effect of the
firm’s overall innovative performance by includ-
ing as a right-hand side variable the flow of its
overall patents (including biotech patents). We also
control for the firm’s relative focus on the genera-
tion of biotech knowledge by including a biotech
focus ratio, the number of biotech patents divided
by total patents. We include the total number of inventors for each firm to control for a firm’s existing knowledge-producing resources. This metric also provides a fine-grained measure of the firm’s innovation-related network size. All time-varying control variables are tracked annually, and are lagged by one year. In addition, we control for the firm’s geographic origin (EU, US). Finally, we include indicator variables that control for firms that were a result of an horizontal merger (merged firms) and firms that are dedicated pharmaceutical firms, that is, not diversified conglomerates (Pharma).

Estimation

The dependent variable is a nonnegative count variable with overdispersion, and therefore, we used negative binomial models. Both fixed- and random-effects specifications would allow us to limit any remaining unobserved heterogeneity (Hamilton and Nickerson, 2003). We conducted a Hausman test which suggested no significant differences between the two estimation methods. Nevertheless, we chose to rely on a firm fixed-effects specification to conduct a conservative within-firm analysis and control for firm-level unobservable factors. As a robustness check, we also used the random-effects specification and the results remained robust.

RESULTS

Table 1 depicts descriptive statistics and bivariate correlations for the variables. Correlations among our independent variables are below the recommended ceiling of 0.70. To further evaluate the threat of collinearity, we estimated the variance inflation factors (VIFs) for each coefficient, with the maximum estimated VIF being 1.64, which is well below the recommended threshold of 10 (Cohen et al., 2003). Table 2 depicts the results of our fixed-effect negative binomial regression predicting the number of incumbent firm-level biotech patents. In Models 2 and 3, we tested Hypothesis 1 by assessing the interactions between external knowledge sourcing and recombinative potential (average path length and clustering). In Models 4 and 5, we tested Hypotheses 2 by inserting the interactions between external knowledge sourcing and coordination costs (average ties per patent and per inventor). Models 1 and 6 are control models. Model 1 is the baseline model with only control variable included, while Model 6 is the complete model with all interactions inserted simultaneously.

We find strong support for our Hypothesis 1 regarding the negative moderation effect of inter-firm recombinatory knowledge potential. In Model 2, exploration alliances are less effective when combined with high internal average path length.
### Table 2. Fixed-effects negative binomial regression predicting number of biotech patents

<table>
<thead>
<tr>
<th>Variable</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
<th>Model 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year effects</td>
<td>(0.041)</td>
<td>(0.038)</td>
<td>(0.038)</td>
<td>(0.040)</td>
<td>(0.039)</td>
<td>(0.037)</td>
</tr>
<tr>
<td>Merged firm</td>
<td>0.120***</td>
<td>0.062*</td>
<td>0.070**</td>
<td>0.096***</td>
<td>0.100***</td>
<td>0.040</td>
</tr>
<tr>
<td>EU</td>
<td>(0.153)</td>
<td>(0.196)</td>
<td>(0.194)</td>
<td>(0.162)</td>
<td>(0.164)</td>
<td>(0.203)</td>
</tr>
<tr>
<td>US</td>
<td>−0.534***</td>
<td>−0.915***</td>
<td>−0.947***</td>
<td>−0.000***</td>
<td>−0.501***</td>
<td>−0.723***</td>
</tr>
<tr>
<td>Pharma</td>
<td>(0.148)</td>
<td>(0.196)</td>
<td>(0.193)</td>
<td>(0.193)</td>
<td>(0.161)</td>
<td>(0.205)</td>
</tr>
<tr>
<td>Overall innovative performance</td>
<td>(0.111)</td>
<td>(0.128)</td>
<td>(0.127)</td>
<td>(0.116)</td>
<td>(0.116)</td>
<td>(0.132)</td>
</tr>
<tr>
<td>Biotech focus</td>
<td>0.333***</td>
<td>0.299***</td>
<td>0.283***</td>
<td>0.331***</td>
<td>0.313***</td>
<td>0.282***</td>
</tr>
<tr>
<td>Network size</td>
<td>(0.019)</td>
<td>(0.020)</td>
<td>(0.021)</td>
<td>(0.020)</td>
<td>(0.020)</td>
<td>(0.021)</td>
</tr>
<tr>
<td>Exploration alliances</td>
<td>(0.000)</td>
<td>(0.000)</td>
<td>(0.000)</td>
<td>(0.000)</td>
<td>(0.000)</td>
<td>(0.000)</td>
</tr>
<tr>
<td>Acquisitions</td>
<td>(0.006)</td>
<td>(0.012)</td>
<td>(0.009)</td>
<td>(0.010)</td>
<td>(0.010)</td>
<td>(0.007)</td>
</tr>
<tr>
<td>Average path length</td>
<td>0.147***</td>
<td>0.133***</td>
<td>0.133***</td>
<td>0.133***</td>
<td>0.133***</td>
<td>0.133***</td>
</tr>
<tr>
<td>Clustering</td>
<td>(0.013)</td>
<td>(0.014)</td>
<td>(0.014)</td>
<td>(0.014)</td>
<td>(0.014)</td>
<td>(0.014)</td>
</tr>
<tr>
<td>Average ties per inventor</td>
<td>0.185***</td>
<td>0.182***</td>
<td>0.182***</td>
<td>0.182***</td>
<td>0.182***</td>
<td>0.182***</td>
</tr>
<tr>
<td>Average ties per patent</td>
<td>(0.018)</td>
<td>(0.018)</td>
<td>(0.018)</td>
<td>(0.018)</td>
<td>(0.018)</td>
<td>(0.018)</td>
</tr>
<tr>
<td>Exploration alliances × average path length</td>
<td>−0.047***</td>
<td>−0.031***</td>
<td>−0.044***</td>
<td>−0.044***</td>
<td>−0.044***</td>
<td>−0.044***</td>
</tr>
<tr>
<td>Exploration alliances × clustering</td>
<td>(0.015)</td>
<td>(0.015)</td>
<td>(0.015)</td>
<td>(0.015)</td>
<td>(0.015)</td>
<td>(0.015)</td>
</tr>
<tr>
<td>Exploration alliances × average ties per inventor</td>
<td>0.001</td>
<td>(0.016)</td>
<td>(0.016)</td>
<td>(0.016)</td>
<td>(0.016)</td>
<td>(0.016)</td>
</tr>
<tr>
<td>Exploration alliances × average ties per patent</td>
<td>−0.067***</td>
<td>(0.015)</td>
<td>(0.014)</td>
<td>(0.014)</td>
<td>(0.014)</td>
<td>(0.014)</td>
</tr>
<tr>
<td>Acquisitions × average path length</td>
<td>−0.014**</td>
<td>(0.008)</td>
<td>(0.007)</td>
<td>(0.008)</td>
<td>(0.007)</td>
<td>(0.008)</td>
</tr>
<tr>
<td>Acquisitions × clustering</td>
<td>−0.006</td>
<td>(0.019)</td>
<td>(0.019)</td>
<td>(0.019)</td>
<td>(0.019)</td>
<td>(0.019)</td>
</tr>
<tr>
<td>Acquisitions × average ties per inventor</td>
<td>−0.043**</td>
<td>(0.019)</td>
<td>(0.019)</td>
<td>(0.019)</td>
<td>(0.019)</td>
<td>(0.019)</td>
</tr>
<tr>
<td>Acquisitions × average ties per patent</td>
<td>−0.014**</td>
<td>(0.014)</td>
<td>(0.014)</td>
<td>(0.014)</td>
<td>(0.014)</td>
<td>(0.014)</td>
</tr>
<tr>
<td>No. of observations/groups</td>
<td>2,426/106</td>
<td>1,751/96</td>
<td>1,751/96</td>
<td>2,356/106</td>
<td>2,356/106</td>
<td>1,751/96</td>
</tr>
<tr>
<td>Chi square</td>
<td>2248.82***</td>
<td>2233.99***</td>
<td>2153.03***</td>
<td>2537.70***</td>
<td>2489.22***</td>
<td>2471.54***</td>
</tr>
</tbody>
</table>

*p < 0.1; **p < 0.05; ***p < 0.01; standard errors in parentheses.

(p < 0.01) and clustering (p < 0.05). In Model 3, acquisitions are less effective when combined with high average path length (p < 0.05). These results are robust in the complete specification (Model 6), except for the interactions with acquisitions as a method to source external knowledge. This might be explained by the fact that strategic alliances in biotech are more aimed toward explicit knowledge transfer than acquisitions of biotech start-ups, which may contain a stronger tacit dimension of knowledge (Higgins and Rodriguez, 2006; Rothaermel and Deeds, 2004).

We find some support for our Hypothesis 2 regarding the negative moderation effect of...
organizing for knowledge generation

internal coordination costs. In Model 4, exploration alliances are less effective when combined with a high level of average ties per patent \((p < 0.01)\) and acquisitions are less effective when combined with a high level of average ties per inventor \((p < 0.05)\), see Model 5. Support for Hypothesis 2 is stronger in the complete estimation because, in addition to the results obtained in Models 4 and 5, the interaction between exploration alliances and average ties per inventor is also significant \((p < 0.05, \text{ see Model 6})\).

Taken together, the pattern of results suggests a view that is consistent with our theory. To provide a more intuitive and clear understanding of these results and uncover additional insights, we display graphically the statistically significant interaction results in Figures 2–6. Figures 2, 3 display the interactions between exploration alliances and average path length, and exploration alliances and clustering, respectively. We see that exploration alliances have a strong positive effect only under conditions of low internal recombinative potential and almost no effect when coupled with strong internal recombinative potential. In Figure 4, we see that acquisitions have a negative effect when coupled with high recombinative potential and a slight positive effect for low recombinative potential. In Figure 5, we depict a striking result: If coordination costs are low, then exploration alliances have a strong positive effect. If, however, coordination costs are high, then exploration alliances are actually harmful for the generation of biotech patents. In Figure 6, we depict a similarly striking result for the case of acquisitions, again with a reversal of slopes as we move from low to high coordination costs and assess the contingent effect of acquisitions. If internal knowledge network coordination costs are low, then acquisitions have a positive effect on generating new knowledge. In contrast, when internal knowledge network coordination costs are high, the effect reverses, with external knowledge sourcing through acquisitions decreasing a firm’s ability to generate new knowledge. In summary, we find consistent support for the contingency model between internal recombinatory potential and coordination costs, on the one hand, and external knowledge sourcing, on the other.

**DISCUSSION**

Incumbent firms in high-tech industries often face competence-destroying technological change. In their effort to adapt and develop new knowledge in a novel paradigm, incumbent firms have several corporate strategy options available to them: internal knowledge development and a wide array of external knowledge sourcing strategies, including alliances and acquisitions. In this study, we made an effort to address a critical question: How effective is external knowledge sourcing under different internal knowledge generation regimes? In particular, we developed a conceptual framework suggesting that the effectiveness of external sourcing partly depends on the state of the internal knowledge production process. In particular, we studied firms’ internal knowledge networks in a fine-grained manner, highlighting opposing forces: value creation...
Our central thesis is: If incumbents already possess a strong potential for internal knowledge recombination or a high level of coordination costs in the internal knowledge generation process, then external sourcing (either via alliances and/or acquisitions) will be less effective in delivering the necessary new knowledge generation. This core argument is based on a simple but powerful idea: If incumbents can generate new knowledge internally, then any external sourcing that also leads to new knowledge trajectories might potentially be substituting for knowledge paths suggested by internal development. There are both cognitive and behavioral reasons to suggest that such substitution between internal and external sourcing may occur in this case (Katz and Allen, 1982; Ocasio, 1997). Similarly, if incumbents are able to generate new knowledge internally and face high coordination costs, then any external source adds to the coordination burden and might have compensating knowledge producing effects. We applied social network concepts and analysis to the emerging internal knowledge networks of incumbents when adapting to a technological discontinuity in order to capture the emergence of two critical firm-level knowledge properties: internal recombinatory potential and internal coordination burden.
We tested our theoretical framework in the global pharmaceutical industry. The results provided robust support for our theoretical framework. Exploration alliances and acquisitions were indeed less effective as knowledge building mechanisms when incumbents had internally the potential for knowledge recombination and already faced high coordination costs. Our core tenet that the effectiveness of external sourcing is contingent on the state of a firm’s internal knowledge process resonates with the recent study by Arora, Belenzon, and Rios (2014), demonstrating that firms with centralized R&D derive more value from internal R&D, but less from external R&D via mergers and acquisitions. While Arora et al. (2014) focused on acquisitions, we also look at strategic alliances in a fine-grained manner. Perhaps more importantly, rather than focusing on the internal firm organizational structure, we take a novel look deep inside the firm and unearth structural features of firm-specific knowledge networks that moderate the effectiveness of external sourcing strategies. Moreover, our study also resonates with Hoang and Rothaermel (2010), who looked, albeit at the R&D project than the firm-level of analysis, at the interactions of different types of external and internal knowledge by evaluating some 400 R&D projects.

We submit that this study makes several contributions to different lines of research. First, we
contribute to the literature on knowledge sourcing and the degree of complementarity between external and internal knowledge sourcing. We build on a growing line of work that seeks to identify the factors that affect the relationship between internal and external knowledge sourcing (Cassiman and Veugelers, 2006; Jacobides, 2008; Rothaermel and Hess, 2007) by highlighting important characteristics of the firm’s internal knowledge base. Our conceptual framework and results are consistent with related work suggesting that it is differences in internal knowledge bases that dictate boundary choices (Jacobides and Hitt, 2005; Jacobides and Winter, 2005; Kogut and Zander, 1992). Our framework is also consistent in its objectives with Capron and Mitchell (2009), who show that the effectiveness of external renewal modes in building new knowledge bases is contingent on the firm’s internal social context. We demonstrate that characteristics deep within firms— their potential for new knowledge generation and the associated coordination costs—are important factors in influencing whether external and internal sourcing mechanisms complement or substitute for each other.

Second, we make a contribution to the burgeoning literature on social and knowledge networks and their effects on firm-level performance heterogeneity. Rather than looking at the individual level of analysis to identify certain structural roles held by key knowledge workers such as star scientists in a firm’s knowledge network (Grigoriou and Rothaermel, 2014; Nerkar and Paruchuri, 2005; Paruchuri, 2010), however, we focus on a firm-level level of analysis to unearth certain structural characteristics of a firm’s entire internal knowledge network that influences firm-level performance.

In line with Rosenkopf and Padula (2008), one of this study’s attempted contribution is the application of social network analysis to incumbents’ internal knowledge networks in order to capture overall firm-level knowledge properties. To move from internal knowledge network structure to firm-level knowledge properties, we rely on recent theoretical insights in the concept of multilevel emergence (Kozlowski et al., 2013). We also build on recent work that describes specifically how lower-level network interactions result in the emergence of higher-level firm level properties such firm-level human capital or network-level outcomes (Moliterno and Mahony, 2011; Ployhart and Moliterno, 2011). By doing so, we extend our collective understanding of the type of inferences that one can make when examining the structure of a firm’s internal knowledge network by adding recombinative potential and coordination costs to the factors considered in prior work such as knowledge transfer or sharing (Brown and Eisenhardt, 1997; Lazer and Friedman, 2007; Reagans and McEvily, 2003; Reagans and Zuckerman, 2001; Reagans et al., 2004; Yayavaram and Ahuja, 2008).

Our approach to study the structure of internal knowledge networks to extract information about knowledge recombination and coordination is also consistent with recent work in the field (Kleinbaum and Stuart, 2014) that seeks to understand coordination costs based on a firm’s network structure. Finally, by connecting knowledge network structure to firm-level knowledge creation, we also help to close a gap in knowledge network research, as identified by Phelps et al. (2012).

Limitations and future research

As any study, this one is not without limitations. First, we emphasized the knowledge-sourcing component embedded in alliances and acquisitions. These corporate strategy levers, however, can be motivated by a slew of strategic objectives other than knowledge sourcing such as market consolidation, transaction costs, real options, preemption of competitors, cost savings, or foreign market entry to name a few (McGahan and Villalonga, 2005). We made every effort, however, to address this problem by focusing on exploration alliances only, which carry a stronger knowledge orientation component as they are partnerships with sources of biotech knowledge, and acquisitions by pharmaceutical incumbents that directly involve (small) biotech firms, where a stronger case that knowledge acquisition is the driver can be made.

Second, we relied on inventor ties to develop intrafirm knowledge networks. We chose co-inventor networks to capture the applied stage of the knowledge production process. This enabled us to create a tighter theoretical and more proximate empirical link between new knowledge development and some of its key drivers. We relied on interpersonal collaboration and the structure of the network to proxy for recombinative potential and coordination costs. Copatenting has been shown to include significant knowledge transfer among the inventors involved (Singh, 2005). Future research can uncover additional ways of capturing these attributes and capture other sources of internal
production costs such as internal social frictions (Capron and Mitchell, 2009), social envy, and comparison costs (Nickerson and Zenger, 2004) as well as organizational structure (Arora et al., 2014). Moreover, future research may also focus on informal ways to generate new knowledge as well as on generating tacit rather than explicit knowledge (captured in patents), as done in this study.

Third, the number of patent counts in a new technological paradigm as dependent variable to proxy new knowledge generation is also not without criticism. Not all patents are created equal (i.e., have the same value in terms of knowledge generation). Also, we are neglecting informal and tacit sources of knowledge generation, which are often quite important to firm-level performance. Although patenting is prevalent and quite important in the pharmaceutical industry, patenting does not always occur for knowledge generation. Firms, for example, patent for a number of different reasons such as competitor preemption, legal strategy, signaling, and so forth. Moreover, there are other important sources of internal network formation such as publication co-authorships or informal collaboration among scientists that our study neglects. Given these other sources of knowledge generation, however, implies that patent counts as proxy for new knowledge generation would actually be a conservative estimate because we cannot capture informal knowledge generation effectively. If anything, using patent counts alone as proxy for knowledge generation would actually bias our estimates downward, and thus, making it harder for us to find statistically significant relationships. Nonetheless, we encourage future research to go beyond patent metrics when assessing firm-level knowledge generation.

Finally, we did not include any measures for the costs of external knowledge sourcing. It is widely documented that both alliances (e.g., knowledge misappropriation, choosing the right partner) and acquisitions (e.g., overpayment, post-acquisition integration), however, have costs. Acquisitions, in particular, can be costly and acquirers often overpay for targets. Future research should address this issue to provide an even more fine-grained understanding of the benefits and cost of external sourcing strategies vis-à-vis internal knowledge networks.

Managerial implications

We conclude with several managerial implications in general, and for corporate strategy in particular. First, we provide managers with a fresh tool of evaluating the state of their firm’s internal knowledge base using social network concepts. Second, we offer theory and evidence on the important role of the firm’s internal recombinative potential and coordination costs when it comes to evaluating the effectiveness of external knowledge sourcing strategies.

Perhaps more important for corporate strategy, we show that external sourcing strategies are less effective when coupled with an internal potential to generate knowledge or with high internal coordination costs. The benefits to an external sourcing mode, however, may be overstated when coupled with a solid state of internal knowledge recombination potential or high coordination costs. Therefore, it is critical to know that if an external sourcing mode is chosen for its knowledge benefits and is evaluated vis-à-vis its commensurate costs.

Both the benefits and cost of external sourcing as well as internal sourcing must be taken into account when organizing for new knowledge generation.

ACKNOWLEDGEMENTS

We thank Nick Argyres, Jay Barney, Teppo Felin, Nicolai Foss, Nathan Furr, Remzi Gozubuyuk, Karin Hoisl, Drew Hess, Matt Higgins, Stelios Kavadias, Karim Lakhani, Atul Nerkar, Alex Oettl, Phanish Puranam, Peter Roberts, Henry Sauermann, Tim Simcoe, Lourdes Sosa, Todd Zenger, and Maurizio Zollo for helpful comments and suggestions. We also thank participants at the Academy of Management Meeting, DRUID Conference, Strategic Management Society Conference, Tilburg Innovation Conference, Industry Studies Conference, and Darden Innovation and Entrepreneurship Conference for comments and suggestions. A prior version of the research won the DRUID Best Paper Award and was a finalist for the Best PhD Paper Award at the Strategic Management Society Conference.

The authors acknowledge support for this research from the National Science Foundation (NSF SES 0545544), Frank T. Rothaermel gratefully acknowledges funding from The Russell and Nancy McDonough Chair. All opinions expressed as well as all errors and omissions are our own.
REFERENCES


Kozlowski SWJ, Chao GT, Grand JA, Braun MT, Kuljanin G. 2013. Advancing multilevel research


Rothaermel FT, Hess AM. 2007. Building dynamic capabilities: innovation driven by individual-, firm-


